Repeated treatment may select resistant cell lineages that cross a threshold for sustained growth
In reconstructed skin, repeated treatment may select initially rare resistant cell lineages whose production of self-renewing basal cells exceeds losses after withdrawal. Baseline samples should predict survival and faster repopulation; failure to predict it alongside functional donor DNA would favor a rival.
Stage of verification
- Hypothesis published2026-09-25
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Ageing mechanism
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Stem cell
Basal cells
Cells whose populations can persist through self-renewal or decline through cell death and differentiation
Where this hypothesis actsDrug-resistant lineages surviving repeated antimetabolite courses in skin, after treatment withdrawal
Hypotheses on this target 1
Reprogramming
Transplantation
Directed differentiation
Proliferation
Population balance1
What is proposed
Population balance
Limit persistence of lineages whose basal cell production exceeds cell loss
With whatNot stated in the record
HowNot stated in the record
Possible result
Possible stabilization of the treatment-associated component of SPV_11
From the recordОграничение числа сохраняющихся сверхкритических линий должно стабилизировать связанный с лечением компонент SPV_11.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Repeated treatment could initially reduce skin lesions while leaving behind cells that repopulate the skin more effectively afterward. The unexpected move is that no surviving cell family needs to acquire a new ability: changing which families remain could change the population from one likely to disappear to one capable of sustained growth. This is a proposal generated by the pipeline, not a measured result.
- Repeated drug courses preferentially spare cell families that were already resistant.
- Differential survival changes which families make up the remaining population.
- After withdrawal, the selected families produce self-renewing basal cells faster than they irreversibly lose them.
- That balance is proposed to shift the surviving population from likely extinction to sustained multiplication.
- The changed mixture produces faster absolute repopulation even though each family's growth properties remain unchanged.
Repeated weeding could leave a garden dominated by plants that were already difficult to remove. The garden could then refill faster even though none of those plants has become a faster grower.
Where the picture breaks: The picture explains selection among existing families, but does not establish a sharp boundary between disappearance and persistence. That additional claim requires measurements of cell production, loss and long-term survival in tissue.
- Master questionstep 01 of 04
Middle-aged human skin is the intended target of a therapy that would restore function toward the state found in young people.
Rests on: The supplied goal explicitly names the population and desired direction of improvement, but does not define which skin functions would establish success.
Stated in the chain - Goal pillarstep 02 of 04
Limiting damage accumulated through repeated repair is selected as a route toward better skin function.
Rests on: The goal supplies the desired improvement, but does not establish repeated repair as a cause of the functional decline being targeted.
AssumptionThe chain assumes that repeated repair produces cumulative damage relevant to restoring middle-aged skin function.
- Gap questionstep 03 of 04
Repeated removal of abnormal cells with an antimetabolite, a drug that interferes with cellular metabolic processes, might accelerate later skin repopulation by resistant clones, families descended from individual cells, despite initially reducing lesions. The question also asks whether that effect recurs after treatment stops.
Rests on: The preceding concern about cumulative damage motivates examining adverse consequences of repeated treatment, but does not supply the connection to this drug class or resistant cell families.
LeapThe supplied material does not establish why repeated antimetabolite treatment is the relevant repair intervention for the master goal, or that it produces the proposed post-treatment acceleration.
- Hypothesisstep 04 of 04
Repeated courses are proposed to preferentially preserve rare, already resistant lineages, meaning cell families with shared ancestry. After treatment stops, these families produce more self-renewing basal cells, cells in the skin's bottom layer that maintain their family through further divisions, than they lose through death or terminal differentiation, the permanent transition out of that self-renewing state. The surviving population would shift from likely disappearance to sustained multiplication without changing each original family's properties.
Rests on: The preceding question supplies repeated treatment, resistant survivors and post-treatment repopulation as the phenomenon to explain. The endpoint supplies the proposed explanation: selection among existing families, with persistence governed by the balance between production and irreversible loss of self-renewing cells.
Stated in the chain
What is carried, and what is not. The single screened source speaks to one background link: how divisions relate to cell fate, meaning whether cells retain or leave a self-renewing state. The 2023 eLife study reports that the protein AGS3 promotes divisions parallel to the skin surface during development of its layered outer covering; it does not establish repeated-treatment selection, post-withdrawal persistence or a growth threshold, and nothing supplied establishes the proposed sequence end to end.
Where the reasoning is carried by something unstated · 2
- Goal pillar. The chain assumes that repeated repair produces cumulative damage relevant to restoring middle-aged skin function.
- Gap question. The supplied material does not establish why repeated antimetabolite treatment is the relevant repair intervention for the master goal, or that it produces the proposed post-treatment acceleration. Establish the missing link before relying on this step.
How a result here could mislead · 3
- A larger percentage of resistant cells could be mistaken for faster repopulation or a transition to sustained growth, even if their absolute number does not increase. What closes it: The proposed reconstructed-skin test, using skin assembled as an experimental model, must track absolute numbers within marked families alongside divisions, permanent loss of self-renewal and deaths. Family persistence must be assessed separately from relative abundance, with the observation period specified in advance.
- An advantage that survives transfer of equal cell numbers into a fresh model could be credited entirely to selection of pre-existing families. Transfer alone does not distinguish selection from newly acquired changes within those families, or exclude a concurrent growth stimulus released by dying cells. What closes it: Preserved samples of the original families must predict survival, and within-family growth rates must be compared before and after treatment. The proposed checks for functional donor deoxyribonucleic acid, or DNA, the molecule carrying inherited information, and for acceleration transferred by liquid containing no cells must be interpreted alongside those comparisons.
- A sharp-looking change in family survival could be treated as confirmation of the borrowed mathematical model even when crowding, cell interactions or a short observation window shape the result. What closes it: The endpoint requires predictions to be checked on independent families before tissue density strongly limits growth. Production and loss rates must be measured rather than inferred from net expansion alone, and finite follow-up cannot establish unlimited persistence.
What would make this wrong. The central explanation would fail if preserved original families did not predict which survivors drive accelerated repopulation, while matched comparisons showed that those survivors acquired increased growth ability after treatment. The threshold component would also fail if measured production and irreversible loss of self-renewing cells did not predict family persistence under the conditions the proposed model is meant to describe.
What it would change. If this held, evaluating repeated skin treatments would require tracking which cell families persist and how they repopulate after withdrawal, alongside the initial reduction in lesions. The proposed route toward the master goal would include limiting survival of families whose self-renewing cell production exceeds their losses. Even a positive result in reconstructed skin would not establish restoration of youthful function in middle-aged humans, and the supplied material does not define SPV_11, the outcome identifier the hypothesis says this intervention should stabilize.
Sources read · 1
AGS3 antagonizes LGN to balance oriented cell divisions and cell fate choices in mammalian epidermis. · eLife · 2023
“Collectively, these data demonstrate that AGS3 promotes planar divisions during epidermal stratification.”
Does not settle: Источник описывает ориентированные деления в развивающемся эпидермисе, но не устанавливает эффекты повторного лечения, отбор лекарственно устойчивых линий, их сохранение после отмены, порог устойчивого роста или компонент SPV_11.
The gap this hypothesis explains
Two live hypotheses pull in opposite directions here, and the field has not chosen between them.
Can repeated removal of abnormal skin cells accelerate growth of drug-resistant cell families, including after treatment stops?
Original wording · exactly as the pipeline generated it
Может ли повторное удаление атипичных клеток антиметаболитом ускорять последующее заселение кожи устойчивыми клонами, несмотря на первоначальное уменьшение поражений, и воспроизводится ли этот эффект после отмены?
What this question is asking
The question concerns whether repeated treatment can reduce visible skin damage while leaving surviving abnormal cells better able to spread. It asks whether an antimetabolite, a drug that interferes with processes needed for cell growth, repeatedly removes susceptible cells and leaves resistant cell families to occupy the treated skin. The comparison is whether those resistant families expand faster because of repeated treatment, both between courses and after treatment stops, and whether the effect occurs consistently. The question assumes an initial reduction in lesions and proposes that competition during skin repair and cells surviving within hair follicles could reverse that early benefit; the supplied evidence does not establish this sequence.
- Antimetabolite
- A class of drugs that interfere with chemical processes cells need to grow and reproduce. The question concerns whether repeated treatment with such a drug could favor surviving abnormal cells.
- 5-fluorouracil
- The antimetabolite named in the supplied sources. Application to the skin and injection into a lesion are different treatment settings represented in those sources.
- Abnormal or atypical cells
- Cells with features that differ from the usual cells in the tissue. This broad description does not by itself establish that a cell is cancerous or resistant to treatment.
- Clone or cell family
- Cells descended from a shared original cell. Growth of a resistant clone means expansion of that family, rather than simply the return of a visible skin patch.
- Drug resistance
- Reduced susceptibility to a drug's effects. Failure of a treatment to clear a lesion does not by itself establish resistance in a particular cell family.
- Lesion
- An area of visibly or otherwise detectably abnormal tissue. Its disappearance and the disappearance of every abnormal cell are distinct outcomes.
- Regenerative selection
- The proposed process in which some surviving cell families gain an advantage as tissue repairs itself. In this question it is a suggested mechanism, not a finding established by the supplied sources.
- Hair follicle or follicular reservoir
- A hair follicle is the skin structure from which a hair grows. Calling it a reservoir proposes that cells survive there and later spread into surrounding skin; that role is not established here.
- Repopulation
- Cells expanding into an area after other cells have been removed. The question specifically concerns repopulation by resistant abnormal cell families.
- Actinic keratosis
- A skin lesion associated with sun damage that can be a precursor to skin cancer. It is the condition discussed in S1, S2, S4, and S5.
- Topical and field-directed treatment
- Topical treatment is applied to the skin surface. Field-directed treatment covers an affected area rather than targeting only an individual visible lesion.
- Imiquimod
- A skin-applied medicine named alongside 5-fluorouracil in the combination treatment described by S5. That combination's reported potential benefit does not identify why earlier treatment failed.
- Squamous cell carcinoma
- A cancer arising from cells that form surface linings, including the skin. S10 concerns an existing skin cancer, a different setting from prevention across an area of skin.
- Biopsy
- Removal and examination of a tissue sample. In S10, this examination provided the reported evidence of cancer clearance.
- Recurrence
- Return of a condition after it has cleared or improved. Recurrence alone does not reveal which cell family produced it or whether treatment caused resistance.
- RL-3
- An undefined label attached to antimetabolite prevention in the supplied gap detail. The input does not establish what treatment or evidence category it denotes.
Antimetabolite prevention produces mainly short-term clinical benefit, while regenerative selection and follicular reservoirs permit subsequent repopulation that could reverse the long-term effect of repeated courses.
The assumption is that treatment initially reduces visible abnormal skin patches, but surviving cell families gain a growth advantage as the skin repairs itself. Hair follicles, the structures from which hairs grow, are proposed as places where abnormal cells can survive and later spread back into treated skin. If established, this would explain how early improvement could coexist with a worse later outcome.
S10 reports clearance of one patient's cancer and no recurrence during five months of follow-up, establishing only a limited example of an early favorable outcome. S4 suggests that follow-up at six to twelve months might better assess treatment effectiveness and recurrence; it does not demonstrate that benefits are mainly short-lived. S1 and S2 identify established treatment options, while S5 discusses combination treatment after previous therapy failed. None of these supplied excerpts establishes selection of resistant cell families, survival within hair follicles, or reversal of long-term benefit. The evidence supplied is too limited to judge the full premise, and the label RL-3 is not defined.S1S2S4S5S10
The same question asked without the part nothing read establishes:
- Does repeated antimetabolite treatment accelerate the expansion of resistant abnormal skin cell families between courses and after treatment stops?
- How does abnormal skin cell growth after repeated antimetabolite treatment relate to the initial change in visible lesions?
- Faster growth persists after treatment stops Under the proposed mechanism, susceptible cells disappear while resistant survivors expand during repair. If that faster expansion continues after treatment ends and occurs consistently, early lesion reduction would not establish lasting control of abnormal cells. An increase in cancer risk would still require separate evidence.
- Faster growth occurs only between courses Repeated treatment would be associated with faster expansion of resistant survivors while courses continue, but that difference would disappear after treatment stops. This would support a treatment-period effect without establishing a lasting reversal of benefit.
- Repeated treatment does not accelerate growth Removing susceptible cells would not translate into faster expansion of resistant cell families. Early improvement would therefore not be undermined by this particular mechanism, although lasting benefit and cancer risk would remain separate questions.
A reduction in visible lesions measures a different outcome from the later growth of abnormal cell families. Under the proposed mechanism, treatment removes susceptible cells, surviving resistant cells expand during repair, and abnormal tissue returns despite the early improvement. If that sequence occurred, judging treatment solely by early clearance could miss a later adverse effect. If it did not occur, treating recurrence as proof that treatment selected resistant cells would wrongly attribute a mechanism that had not been demonstrated. The supplied material does not connect either outcome to the question's ten-year cancer-risk requirement.
Антиметаболитная профилактика, RL-3, даёт преимущественно краткосрочный клинический эффект; регенеративный отбор и фолликулярные резервуары допускают последующее заселение.
Рост патологических клонов между курсами и после отмены остаётся в заданных пределах; избыточный онкологический риск приемлем на десятилетнем горизонте.
Не проверено, меняют ли повторные курсы знак долгосрочного эффекта через отбор устойчивых клонов, скрытый ранним уменьшением поражений.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Проверяемая гипотеза: повторные курсы преимущественно сохраняют исходно редкие лекарственно устойчивые линии, у которых после отмены число новых самоподдерживающихся базальных клеток превышает число клеток, утрачиваемых вследствие гибели и окончательной дифференцировки. Популяция выживших пересекает порог между вероятным угасанием и устойчивым размножением. Поэтому абсолютное заселение после отмены ускоряется при неизменных свойствах каждой исходной линии. Состояние хранится в составе выживших линий, а порог определяется балансом клеточных судеб. Ограничение числа сохраняющихся сверхкритических линий должно стабилизировать связанный с лечением компонент SPV_11.
Where the idea comes from
The hypothesis borrows a result from another field. This is what it borrows, and from where.
Неравновесные фазовые переходы в поглощающее состояние; приближение процесса рождения и гибели к модели контактного процесса Харриса. Для раннего роста одной линии E[dN/dt]=(b−d)N, R=b/d. Здесь t означает время после отмены, N — абсолютное число самоподдерживающихся базальных клеток этой линии, E — математическое ожидание, b — скорость появления дополнительной такой клетки в расчёте на одну исходную клетку, d — скорость её необратимой утраты вследствие гибели или дифференцировки; b и d имеют размерность сутки⁻¹, R безразмерно. При постоянных независимых скоростях и одной начальной клетке вероятность неограниченного сохранения равна нулю при R≤1 и 1−1/R при R>1; характерное время изменения среднего числа клеток τ=1/|b−d| возрастает у порога. τ измеряется в сутках. Это приближение для ранней динамики, а не точный закон для конечного эпидермиса: взаимодействия клеток и конечный размер ткани требуют оценки по данным. Предлагаемый переход относится к воспроизводству клеточных линий при фиксированной архитектуре ткани. [Harris, Contact Interactions on a Lattice, 1974](https://doi.org/10.1214/aop/1176996493).
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
Параллельно сохранённые образцы исходных линий позволят предсказать, какие из них переживут повторные курсы и дадут ускоренное заселение. После переноса одинакового числа выживших клеток в свежую контрольную модель преимущество сохранится, но скорость размножения отдельной линии будет совпадать с её скоростью до лечения. При плавном изменении измеренного отношения рождения и утраты базальных клеток вероятность длительного сохранения линии резко изменится около критической области, а время угасания увеличится при приближении к ней снизу. Отсутствие прогностической силы исходных свойств при появлении функциональной донорской ДНК поддержит IH_Q_L3_M_G4_1_01; перенос ускорения бесклеточной средой поддержит IH_Q_L3_M_G4_1_03.
Would tell it apart from at least one rival. The prediction specifies persistence of an advantage after equal-cell transfer, unchanged within-lineage proliferation rates, and changes in lineage persistence and extinction time near a critical region. These are measurable comparisons. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Начальный тест выполним на помеченных линиях в реконструированной коже с регистрацией делений, дифференцировки и гибели. Прогнозы модели следует проверять на независимых линиях и до выраженного ограничения роста плотностью ткани. Простое увеличение относительной доли устойчивых клеток критический переход не подтверждает.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
Параллельно сохранённые образцы исходных линий позволят предсказать, какие из них переживут повторные курсы и дадут ускоренное заселение. После переноса одинакового числа выживших клеток в свежую контрольную модель преимущество сохранится, но скорость размножения отдельной линии будет совпадать с её скоростью до лечения. При плавном изменении измеренного отношения рождения и утраты базальных клеток вероятность длительного сохранения линии резко изменится около критической области, а время угасания увеличится при приближении к ней снизу. Отсутствие прогностической силы исходных свойств при появлении функциональной донорской ДНК поддержит Genetic material from killed skin cells may drive drug resistance and regrowth in survivors; перенос ускорения бесклеточной средой поддержит Dying cells may speed skin recolonization through prostaglandin E2 release.
- Rival 01 of 02What would separate them
Genetic material from killed skin cells may drive drug resistance and regrowth in survivors predicts: В потомстве нескольких независимо помеченных выживших линий появятся последовательности погибших донорских клонов с подтверждёнными участками включения в геном. Новые сочетания будут сохраняться после удаления препарата и повторного выращивания клеток в общей контрольной среде. Удаление приобретённого участка должно одновременно устранять дополнительную лекарственную устойчивость и ускорение роста. Если ускорение полностью объясняется исходными свойствами выживших линий либо исчезает после смены среды, гипотеза уступает соответственно this hypothesis или Dying cells may speed skin recolonization through prostaglandin E2 release. Одного обнаружения чужой ДНК внутри клетки недостаточно.
- Rival 02 of 02Dying cells may speed skin recolonization through prostaglandin E2 release
Not yet published.
What would separate themDying cells may speed skin recolonization through prostaglandin E2 release predicts: Бесклеточная среда, полученная после удаления препарата из модели с продолжающейся гибелью клеток, ускорит рост ранее не леченных контрольных линий. Эффект воспроизведёт измеренная концентрация простагландина E2, а блокирование его рецепторного действия на клетки-реципиенты устранит ускорение. При повторном выращивании выживших линий в свежей среде дополнительное преимущество исчезнет. Ускорение, сохраняющееся после прекращения гибели и продукции простагландина E2, опровергнет эту гипотезу как достаточное объяснение и поддержит наследуемые механизмы Genetic material from killed skin cells may drive drug resistance and regrowth in survivors или this hypothesis.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.